Genmab A/S (NASDAQ:GMAB) Earns “Buy” Rating from Truist Financial

Truist Financial restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Tuesday morning, Benzinga reports. Truist Financial currently has a $50.00 target price on the stock.

GMAB has been the subject of several other reports. Citigroup lowered Genmab A/S from a neutral rating to a sell rating in a report on Monday, January 22nd. HC Wainwright reiterated a buy rating and set a $50.00 price target on shares of Genmab A/S in a report on Wednesday, March 6th. UBS Group upgraded Genmab A/S from a neutral rating to a buy rating in a report on Wednesday, December 6th. Finally, BMO Capital Markets upgraded Genmab A/S from a market perform rating to an outperform rating and lifted their price target for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Hold and a consensus price target of $48.50.

Genmab A/S Trading Down 2.4 %

Shares of NASDAQ GMAB opened at $29.91 on Tuesday. Genmab A/S has a one year low of $26.32 and a one year high of $42.99. The firm has a market capitalization of $19.76 billion, a PE ratio of 31.16, a PEG ratio of 1.44 and a beta of 0.98. The business has a 50-day moving average price of $28.88 and a two-hundred day moving average price of $31.09.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.02. The business had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. Research analysts anticipate that Genmab A/S will post 1.09 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. increased its position in Genmab A/S by 1.7% in the 1st quarter. Rockefeller Capital Management L.P. now owns 18,508 shares of the company’s stock worth $698,000 after buying an additional 310 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Genmab A/S by 5.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 6,268 shares of the company’s stock worth $221,000 after purchasing an additional 337 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Genmab A/S by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 41,715 shares of the company’s stock worth $1,586,000 after purchasing an additional 408 shares in the last quarter. HBK Sorce Advisory LLC grew its holdings in shares of Genmab A/S by 4.8% during the 3rd quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock worth $322,000 after purchasing an additional 419 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Genmab A/S by 86.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after purchasing an additional 498 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.